The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Improved Biomarkers and Clinical Outcome Measures, 2019International Validation of Two Non-motor Symptom Scales in Parkinson’s Disease
Study Rationale:
Non-motor Parkinson’s symptoms can fluctuate with dopaminergic medication effectiveness. Anxiety, sadness, lack of energy and fatigue are common symptoms during the off-medication... -
Parkinson’s Disease Therapeutics Pipeline Program, 2024Investigation of a Novel Therapeutic Approach for Non-motor Symptoms of Parkinson’s Disease
Study Rationale:
Parkinson's disease (PD) is characterized by both motor symptoms and non-motor symptoms. While progress has been made in addressing motor symptoms, non-motor...
-
Summer 2025 RFA: Personalized Approaches for Understanding, Assessing and Improving Gait in Parkinson’s Disease Research Program, 2025Predicting Freezing of Gait in Parkinson’s Disease: An Objective Quantitative Exploration Combining Patient Perception with Multi-Dimensional Digital Gait Analysis & Multi-Domain Cognitive Testing
Study Rationale: Freezing of gait (FOG) is a debilitating – and not well understood - symptom impacting many patients with Parkinson’s disease (PwPD). FOG can occur during any stage of the disease but...
-
Defining Cognitive Phenotypes of Parkinson’s Disease, 2011The Relationship Between Cognitive Phenotypes of PD with Visual Hallucinations and 5HT2A Receptors in the Inferotemporal Cortex
Objective/Rationale:
The project aims to understand the mechanisms underlying cognitive deficits that are associated with visual hallucinations (VH) in Parkinson’s disease (PD). We have previously... -
Repositioning Drugs for PD, 2011Evaluation of a Specific DAT Inhibitor in Pre-clinical Models of Parkinson's Disease
Objective/Rationale:
MLR-1017 is a psychostimulant drug used clinically for a variety of neuropsychiatric and other applications, but has never been tested in Parkinson’s disease (PD). Levodopa is a... -
Therapeutic Pipeline Program, 2015Improving Access to Depression Care in Parkinson’s Disease: A Telehealth Approach
Study Rationale:
There is a critical need for treatments that address depression and barriers to care among the approximately 5 million people living with Parkinson’s disease (PD)...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.